InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.00%
)
US TECH 100
19,326.00
(
0.32%
)
Dow Jones
39,164.06
(
0.00%
)
Brent Oil
85.48
(
0.07%
)
Bitcoin
61,303.71
(
-0.50%
)
Post# of 252412
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: poorgradstudent post# 151808

Tuesday, 11/06/2012 12:53:19 AM

Tuesday, November 06, 2012 12:53:19 AM

Post# of 252412

Against: As an ONXX shareholder, I would not be in favour of an in-licensing. Due to point #3, I think that ARRY is showing their hand and I would use that as leverage. Maybe provide some free drug and help a little bit with trial costs, but not much more.

Appreciate the comments pgs. Regarding point #3, I think ARRY could have some degree of leverage themself as, provided the data agrees, there's the potential for 520+bortezomib combo instead of 520+carfilzomib.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up